618 Special Offer | 10 Million Sorted CD3+ T Cells for Only ¥618
Release Date:
2025-07-04 15:17
The Key Carrier for Deciphering the Immune Code
The moment T cells traverse the vascular endothelium and precisely recognize cancer-specific targets, all the rigorous preclinical screening is truly worthwhile.
In the cutting-edge fields of cancer immunotherapy and cell therapy research and development, high-purity, highly active CD3+ T cells have always been the cornerstone for overcoming key bottlenecks. However, the presence of contaminating irrelevant cells and poor cell viability in commonly available commercial products has led countless research teams to waste both funding and time on repeated experiments and data discrepancies.
618 Special Limited-Time Sale!
｜Wishing all candidates a bright future
Alliance Promotion: Hycells & InnoScience
Limited-Time Special Offer Week
June 16–20, 2025
Limited-time, unbeatable deals for 618! Hycells and InnoCell have joined forces to launch a groundbreaking one-stop solution for T-cell manufacturing!
✅ PBMC samples (provided by Hycells) + T-cell negative selection kit (provided by InnoSe) = high-quality 10 million CD3+ T cells
✅ Rigorous quality control: high purity and high activity, ensuring the reliability of your research data!
✅ Saves time and effort: No need for tedious sorting steps—directly obtain ready-to-use T-cell samples!
✅ Flexible Selection: Both fresh and cryopreserved CD3+ T-cell samples are available to meet diverse experimental needs. For fresh orders, delivery is limited to same-day reachable areas such as Shanghai and Suzhou; each customer is restricted to a maximum of two orders per unit. Customers outside the Shanghai area are responsible for their own cold-chain shipping costs.
Limited quantities—first come, first served! Secure top research products for 618 and accelerate your research progress! Consult now to enjoy exclusive offers! Contact: Mr. Xie, 15201775322. The final interpretation of this event is reserved by Hycells Biotechnology and InnoScience!
“We deliver not only cell samples, but also a traceable chain of research evidence.” — Hycells Technical Team
CD3+ T Cell Sample Detail Sheet:
CD3+ T-cell sample (negative selection, cryopreserved) Certificate of Analysis File:
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board